Some plasma-derived antithrombin products have a label that includes acquired deficiencies in certain European countries. Based on your information, Germany is presumably one of these countries.
Although it makes sense from a medical standpoint to substitute ATryn in any indication where a plasma-derived AT has been used, it unfortunately does not follow that ATryn will be reimbursed for use in an acquired antithrombin deficiency just because a plasma-derived antithrombin product has such a label. Regards, Dew
Market Data 
Markets 
AI
